AWARE Study

Artificial Intelligence for Widespread Awareness, Research and Education (AWARE): Establishing the Framework for Tailored AI Tools for Multiple Myeloma

Overview

Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) disproportionately affect Black and African American individuals, who experience higher incidence, earlier onset, and worse outcomes than other groups. Yet these conditions receive far less public attention, leaving many patients and families without accessible, trustworthy information.

The AWARE Study explores how people from diverse racial and ethnic backgrounds feel about using artificial intelligence (AI) tools—such as conversational chatbots or digital avatars—to support cancer education and communication. Insights from this project will guide the development of a culturally tailored, AI‑powered assistant designed to support individuals living with MM or MGUS throughout their care journey.

This project is funded by M‑CARES and represents Phase 1 of a three‑phase research program.

Purpose of the Study

The goal of this study is to understand how patients and community members think about, understand, and feel about generative AI tools in cancer care. We are especially interested in perspectives from:

Black/African American individuals
Hispanic/Latino individuals
White individuals
People living with MM or MGUS
Community members without a cancer diagnosis

Your input will help ensure future AI tools are trustworthy, culturally responsive, and genuinely useful for diverse communities.

Study Goals

The AWARE Study focuses on three primary aims:

1. Attitudes & Willingness to Use AI

Understand knowledge of, attitudes toward, and willingness to use generative AI tools in healthcare and cancer care.

2. Community Perspectives

Explore concerns, preferences, and expectations related to AI through focus group discussions.

3. Framework Development

Use survey and interview findings to build a framework for designing culturally tailored AI tools to support MM and MGUS education and care.

Why This Study Matters

Black/African American individuals are diagnosed with multiple myeloma more often, at younger ages, and at later stages than White individuals.
There is limited research on how underrepresented communities perceive AI in cancer care.
Trust, privacy, cultural relevance, and clear communication are essential when introducing new technologies into healthcare.

By listening directly to patients and community members, this study ensures future AI tools are designed with communities, not just for them.

Who Can Participate?

You may be eligible if you:

Are 18 years or older
Self‑identify as Black/African American, White, or Hispanic/Latino
Are living with MM or MGUS or are a community member without a cancer diagnosis

What Participation Involves

1. Survey (One‑Time)

Can be completed online, on paper, or in person
Covers knowledge of AI, attitudes toward AI in healthcare, and comfort using AI for cancer information
Takes approximately 15–20 minutes

2. Focus Group (Selected Participants)

Small group discussion with 6–8 participants
Conducted in person or virtually
Offered in English or Spanish
Explores trust, concerns, benefits, and preferences related to AI in cancer care
Lasts approximately 60–90 minutes

There are no medical treatments or interventions involved in this study.